Loss of oncosuppressive function of LKB1 confers peculiar characteristics to NSCLC, including clinical aggressiveness, resistance to immunotherapy, and enhanced sensitivity to metabolic stress. Here, STK11 is linked to non-small cell lung carcinoma.